Brief: Alterity Therapeutics Says ATH434-201 Trial Remains On Track
31/07/2023 11:14
July 31 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY THERAPEUTICS LTD - ATH434-201 TRIAL REMAINS ON
TRACK
TO COMPLETE ENROLLMENT IN Q3 OF 2023 WITH TOP-LINE DATA EXPECTED
BY END OF 2024
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital